Jaguar Health (NASDAQ:JAGX) and Eleven Biotherapeutics (NASDAQ:EBIO) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, risk, profitability, analyst recommendations and institutional ownership.
This is a breakdown of recent ratings and recommmendations for Jaguar Health and Eleven Biotherapeutics, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Institutional & Insider Ownership
5.5% of Jaguar Health shares are held by institutional investors. Comparatively, 14.0% of Eleven Biotherapeutics shares are held by institutional investors. 4.7% of Jaguar Health shares are held by company insiders. Comparatively, 28.7% of Eleven Biotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
This table compares Jaguar Health and Eleven Biotherapeutics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Risk & Volatility
Jaguar Health has a beta of -0.78, meaning that its share price is 178% less volatile than the S&P 500. Comparatively, Eleven Biotherapeutics has a beta of 2.75, meaning that its share price is 175% more volatile than the S&P 500.
Earnings & Valuation
This table compares Jaguar Health and Eleven Biotherapeutics’ top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Jaguar Health||$4.36 million||6.63||-$21.96 million||N/A||N/A|
|Eleven Biotherapeutics||$430,000.00||365.65||-$29.02 million||($1.11)||-2.96|
Jaguar Health has higher revenue and earnings than Eleven Biotherapeutics.
Eleven Biotherapeutics beats Jaguar Health on 8 of the 11 factors compared between the two stocks.
About Jaguar Health
Jaguar Health, Inc., a commercial stage natural-products pharmaceuticals company, focuses on developing gastrointestinal products for human prescription use and animals worldwide. The company, through its wholly-owned subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and commercializing proprietary human gastrointestinal pharmaceuticals for the global marketplace from plants used traditionally in rainforest areas. Its human health product pipelines include Mytesi, which is Phase II clinical trial for the treatment of cancer therapy-related diarrhea, as well as for the supportive care for inflammatory bowel disease; formulation of crofelemer that is Phase II clinical trial for the treatment of short bowel syndrome, congenital diarrheal disorders, and irritable bowel syndrome – diarrhea predominant diseases; and SB-300, a second-generation anti-secretory agent for multiple indications, including cholera. The company's animal health product candidates comprise Canalevia, an animal prescription drug product candidate intended for treatment of various forms of diarrhea in dogs; and Equilevia is Jaguar's non-prescription product for total gut health in equine athletes. In addition, the company's products include Neonorm Calf and Neonorm Foal. Jaguar Health, Inc. is headquartered in San Francisco, California.
About Eleven Biotherapeutics
Eleven Biotherapeutics, Inc., a biologic oncology company, focuses on the design and development of targeted protein therapeutics (TPTs). It develops products based on its proprietary TPT platform and focused on addressing areas of unmet medical needs in cancer. The company's lead product candidates include Vicinium that is in Phase 3 clinical trial in the United States and Canada for the treatment of non-muscle invasive bladder cancer; and Proxinium for use in treating squamous cell carcinoma of the head and neck. It is also developing systemically-administered TPTs, including VB6-845d for the treatment of multiple types of epithelial cell adhesion molecule positive solid tumors. Eleven Biotherapeutics, Inc. has a cooperative research and development agreement with the National Cancer Institute on the development of the company's targeted therapeutic, Vicinium in combination with AstraZeneca's immune checkpoint inhibitor, ImfinziTM (durvalumab), for the treatment of non-muscle invasive bladder cancer. The company was founded in 2008 and is based in Cambridge, Massachusetts.
Receive News & Ratings for Jaguar Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jaguar Health and related companies with MarketBeat.com's FREE daily email newsletter.